ADRB3 and Urinary urgency: One of these novel compounds is vibegron (VBG, Fig. 1a), a selective beta-3 adrenergic receptor agonist, which has been lately permitted by the Food and Drug Administration (FDA) for treating overactive bladder syndrome [1].